Rosa Garcia-Verdugo
Rosa García-Verdugo studied biochemistry and, after several years at the bench, completed a PhD in Neurobiology at the Max Planck Institute. She is the author of Genética eres tú (Paidós/Grupo Planeta), a popular science book on genetics, and the founder of starvingneuron.com. She contributes to science outreach networks in Spanish and English, and works as a freelance science communicator and medical writer serving biotech companies and European research institutions.-
Edvard Moser: "Neuroscience is evolving at an accelerated speed"
Interview with Prof. Edvard Moser. On 12 October, the Panel for the Future of Science and Technology (STOA), in collaboration with the International Brain Initiative (IBI) and the Kavli Foundation, organised a workshop at the European Parliament entitled "The International Brain Initiative – Shaping... -
A scientist’s opinion: Interview with Ira Haavisto about the EU Project HERoS
Interview with Ira Haavisto, Senior Research Manager at the Nordic Healthcare Group Finland, responsible for the public healthcare system analysis work package of the EU-funded Health Emergency Response in Interconnected Systems project. Why was intensive care unit occupancy an interesting research... -
A scientist’s opinion: Interview with Gyöngyi Kovacs about the EU Project HERoS
Interview with Gyöngyi Kovacs, Erkko Professor in Humanitarian Logistics at the Hanken School of Economics (Finland) and coordinator of the EU-funded Health Emergency Response in Interconnected Systems project. What inspired the Health Emergency Response in Interconnected Systems (HERoS) project?... -
HERoS: How can we improve our response to health emergencies?
A European research consortium (HERoS) was set up to learn from the present COVID-19 pandemic and to provide decision-makers with the necessary information and tools to more efficiently and effectively respond to future disease outbreaks. Some outcomes of this collaboration include a tool to optimise...
-
Tocilizumab : a treatment alternative in COVID-19 pneumonia
Patients with severe COVID-19 pneumonia often need to be mechanically intubated and have an increased mortality risk. Tocilizumab, a drug used against the cytokine storm underlying this clinical condition, has shown positive effects in clinical trials.
-
A scientist’s opinion : Interview with Prof Cristina Mussini about covid-19 treatment
Interview with Professor Cristina Mussini, Head of the Department of Infectious Diseases and Tropical Medicine at the University of Modena and Reggio Emilia in Italy and member of the European AIDS Clinical Society. She has been actively involved in various recent studies on the clinical use of tocilizumab... -
A scientist’s opinion : Interview with Dr Andrew Ip about covid-19 treatment
Interview with Dr Andrew Ip, a specialist in hematology/oncology at the John Theurer Cancer Center at Hackensack University Medical Center, USA, who has been involved in research on tocilizumab use in COVID-19 patients. Why did you choose tocilizumab to treat patients with COVID-19 pneumonia? Andrew... -
A scientist’s opinion : Interview with Dr Juan Victor San-Martin Lopez about covid-19 treatment
Interview with Dr Juan Victor San-Martín López, a physician specialising in infectious diseases and a member of the task force coordinating responses to the leishmaniasis outbreak in 2011 and to COVID-19 at the Hospital Universitario de Fuenlabrada, Spain. He reports on his experience with tocilizumab...